Mayne Pharma agrees A$604 million takeover by Gedeon Richter as shares surge
Australian drugmaker Mayne Pharma agrees to a A$604 million takeover by Hungary's Gedeon Richter, lifting its shares 86% to a one-year high. The offer values Mayne at A$6.40 per share, nearly double its previous closing price, and comes after an earlier sale attempt collapsed over national interest concerns.
Highlights
- Gedeon Richter will acquire Mayne Pharma for A$604 million, offering A$6.40 per share—a 99.4% premium to Monday’s close—pending regulatory and other approvals.
- Richter aims to leverage Mayne’s estetrol-based contraceptive pill and commercial network to expand in the U.S. women’s health market and address unmet medical needs.
- The deal succeeds a blocked A$672 million bid by Cosette Pharmaceuticals, with Australian regulators emphasizing Mayne's strategic manufacturing role and 200 Adelaide plant jobs.
Takeover terms and approval conditions
As reported by Reuters, Gedeon Richter has agreed to acquire Mayne Pharma in a deal that gives the Australian company an equity value of about A$604 million, or $407.76 million. The offer price of A$6.40 a share represents a 99.4% premium to Mayne's closing price on Monday, with the stock last trading at A$5.97 and on track for its best session on record if gains hold.Mayne Pharma Chair Bruce Robinson says the board has carefully considered Richter's proposal and has unanimously concluded it is in shareholders' best interests, in the absence of a superior proposal and subject to an independent expert's conclusion. The scheme also remains subject to regulatory approvals and other conditions, including completion of the sale of Mayne's international business segment to Evaris Pharma.
Women's health strategy and Australian manufacturing backdrop
Richter Deputy CEO László Kovács says Mayne's existing portfolio, including its estetrol-based combination contraceptive pill, and its commercial footprint provide a base for expansion in the U.S. women's health market. He says the acquisition would help the company bring new treatments to millions of women across several therapeutic segments where unmet medical need remains significant.The transaction follows a nearly two-year dispute between Mayne and U.S.-based Cosette Pharmaceuticals, which had sought to withdraw from its A$672 million offer after citing a material adverse change in Mayne's business and finances. Australia blocked that proposed deal last year on national interest grounds after Cosette threatened to close Mayne's Adelaide manufacturing plant, which employs about 200 people and is one of the company's two main factories.
Mayne produces branded and generic medicines focused on women's health, dermatology and infectious diseases, making the company a strategic asset in Australia's pharmaceutical sector.
In earlier coverage, we examined Proofpoint’s debt sale to finance its planned acquisition of Varonis Systems.